Most recently, Butzke et al. [33] evaluated the UGT1A1 genotyping from a German statutory health insurance perspective and found that genotyping prior to irinotecan-based chemotherapy dominates non-guided colon cancer care in Germany. Here, UGT1A1 is linked to malignant colon neoplasm.